Ziopharm Oncology (ZIOP) Reports In-Line Q2 EPS

Ziopharm Oncology (NASDAQ: ZIOP) reported Q2 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $1.66 million.

For earnings history and earnings-related data on Ziopharm Oncology (ZIOP) click here.

You May Also Be Interested In

• BayCom Corp (BCML) Misses Q1 EPS by 4c
• Oceanfirst Financial (OCFC) Tops Q1 EPS by 3c
• Provident Financial Services (PFS) Tops Q1 EPS by 3c